Cardiac Ablation Market Report 2025

The cardiac ablation market size has grown rapidly in recent years. It will grow from $4.31 billion in 2024 to $4.9 billion in 2025 at a compound annual growth rate (CAGR) of 13.9%. The growth in the historic period can be attributed to the rising prevalence of atrial fibrillation, the increasing geriatric population, growing awareness of minimally invasive procedures, enhanced diagnostic capabilities, expansion of healthcare infrastructure, and the increasing demand for effective arrhythmia treatments.

The cardiac ablation market size is expected to see rapid growth in the next few years. It will grow to $8.15 billion in 2029 at a compound annual growth rate (CAGR) of 13.6%. The growth in the forecast period can be attributed to the increasing adoption of minimally invasive procedures, rising demand for outpatient cardiac treatments, the growing geriatric population with arrhythmias, the expansion of telehealth diagnostics for early arrhythmia detection, and rising healthcare investments in emerging economies. Key trends expected during the forecast period include advancements in high-density mapping technologies, integration of AI and robotics, development of next-generation ablation catheters, adoption of cryoablation and pulsed field ablation techniques, and the increasing use of real-time imaging and navigation systems.

The rising incidence of cardiac diseases is expected to drive the growth of the cardiac ablation market going forward. Cardiac diseases encompass a range of conditions affecting the heart's structure and function, including coronary artery disease, heart failure, and arrhythmias. The increase in cardiac diseases is attributed to sedentary lifestyles, which contribute to obesity, hypertension, and poor cardiovascular health. Cardiac ablation supports the management of these conditions by precisely targeting and eliminating faulty electrical pathways in the heart, restoring normal rhythm, reducing symptoms such as palpitations and fatigue, and decreasing dependence on long-term medications. For instance, in December 2023, according to the Australian Institute of Health and Welfare, an Australia-based government agency, doctor-certified coronary heart disease deaths rose from 14,100 in 2021 to 14,900 in 2022. Therefore, the rising incidence of cardiac diseases is driving the growth of the cardiac ablation market.

Prominent companies in the cardiac ablation market are focusing on developing advanced products, such as high-precision mapping catheters, to improve procedural efficiency, enhance diagnostic accuracy, and reduce complications. High-precision mapping catheters are specialized devices used in cardiac ablation to create detailed 3D maps of the heart's electrical activity, allowing precise identification and treatment of arrhythmias. For instance, in September 2022, Biosense Webster Inc., a US-based medical device company, launched the OCTARAY Mapping Catheter with TRUEref Technology. This catheter features eight high-resolution mapping electrodes to provide superior signal fidelity and accurate electroanatomical mapping, while TRUEref technology delivers reliable reference signals, reducing noise and enhancing the clarity of cardiac maps. It enables physicians to perform faster, more efficient procedures with greater confidence in diagnosing and treating complex arrhythmias.

In August 2022, Medtronic plc, a US-based medical equipment manufacturing company, acquired Affera Inc. for an undisclosed amount. Through this acquisition, Medtronic aims to expand its cardiac ablation portfolio by integrating Affera’s advanced mapping and navigation systems, including the Sphere-9 pulsed field and radiofrequency ablation catheter, enhancing its capabilities in treating cardiac arrhythmias. Affera Inc. is a US-based medical device company specializing in cardiac ablation technologies for heart rhythm disorders.

Major players in the cardiac ablation market are Johnson & Johnson, Abbott Laboratories, Medtronic plc, The Sherwin-Williams Company, Toray Industries Inc., GE HealthCare, PPG Industries Inc., Boston Scientific Corporation, AkzoNobel N.V., Alcon Laboratories Inc., Olympus Corporation, CathRx Ltd., Teleflex Incorporated, CONMED Corporation, Lepu Medical Technology (Beijing) Co. Ltd., MicroPort Scientific Corporation, AtriCure Inc., Japan Lifeline Co. Ltd., Mankiewicz Gebr. & Co. (GmbH & Co. KG), AngioDynamics Inc.

North America was the largest region in the cardiac ablation market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in cardiac ablation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cardiac ablation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

Cardiac ablation is a minimally invasive procedure used to treat abnormal heart rhythms, or arrhythmias. The procedure involves creating microscopic scars in targeted areas of heart tissue to block or eliminate faulty electrical pathways that cause arrhythmias. Cardiac ablation is performed using heat (radiofrequency) or cold (cryoablation) and is typically recommended when medications are ineffective or cause significant side effects.

The primary product types of cardiac ablation include radiofrequency (RF) ablators, electrical ablators, cryoablation devices, ultrasound ablators, and others. Radiofrequency (RF) ablators use heat generated from radiofrequency energy to destroy abnormal tissue and are commonly employed in cancer treatment, pain management, and cardiac arrhythmia correction. These devices incorporate various technologies, including conventional, advanced, hybrid, and robotic-assisted systems. Applications include treatment of atrial fibrillation and flutter, tachycardia, and other arrhythmias, serving end users such as hospitals, ambulatory surgical centers, cardiac centers, and other healthcare facilities.

The cardiac ablation market research report is one of a series of new reports that provides cardiac ablation market statistics, including the cardiac ablation industry global market size, regional shares, competitors with the cardiac ablation market share, detailed cardiac ablation market segments, market trends, and opportunities, and any further data you may need to thrive in the cardiac ablation industry. This cardiac ablation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cardiac ablation market consists of revenues earned by entities by providing services such as electrophysiological mapping, pre- and post-operative diagnostics, patient monitoring, and follow-up care for the management of cardiac arrhythmias. The market value includes the value of related goods sold by the service provider or included within the service offering. The cardiac ablation market also includes sales of ablation catheters, ablation generators, energy device systems, mapping and navigation systems, and accessory devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.